Comparative incidence of acute kidney injury in patients on vancomycin therapy in combination with cefepime, piperacillin-tazobactam or meropenem
| Autor: | Nicole G. Harriott, Lan Duong, Sarah Pan-Chen, Dhakrit Rungkitwattanakul, Amy L. Ives |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
medicine.medical_specialty medicine.drug_class Cefepime Antibiotics Meropenem Nephrotoxicity Vancomycin Internal medicine polycyclic compounds Humans Medicine Pharmacology (medical) Retrospective Studies Piperacillin Pharmacology business.industry Incidence Incidence (epidemiology) Acute kidney injury Acute Kidney Injury biochemical phenomena metabolism and nutrition medicine.disease Anti-Bacterial Agents Piperacillin Tazobactam Drug Combination Infectious Diseases Oncology Piperacillin/tazobactam Drug Therapy Combination business medicine.drug |
| Zdroj: | Journal of Chemotherapy. 34:103-109 |
| ISSN: | 1973-9478 1120-009X |
| Popis: | Recent studies have shown that the incidence of nephrotoxicity increases when vancomycin is combined with a beta-lactam antibiotic. The objective of this study was to compare the incidence of acute kidney injury (AKI) in adult patients who received vancomycin with either piperacillin-tazobactam (VPT), cefepime (VC), or meropenem (VM). This was a single center retrospective chart review. Patients were included if they were 18 years or older, received 48 hours of combination therapy and antibiotics were started within 24 hours of each other. Exclusion criteria were receiving more than one combination of antibiotics, serum creatinine1.2 mg/dL, AKI at the time of inclusion, or any form of renal replacement therapy. Two hundred patients met inclusion criteria. A total of 27 (13%) patients experienced AKI. The incidence of AKI was 21.6%, 9%, and 7.4% in the VPT, VC and VM groups, respectively. A patient who received VPT was 5 times more likely to develop AKI when compared to a patient who received VC (adjusted OR 5.09 95% CI (1.51-17.08) |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|